AgilityBio

Agility Biotherapeutics was a pre-clinical stage biotechnology company focused on developing a new class of 'Smart Bispecific' antibody therapies for cancer. The company's proprietary Agility platform was designed to engineer multi-specific antibodies that could more effectively target complex tumor environments, with a primary focus on HER2-positive malignancies. Founded by industry veterans, the company aimed to overcome the limitations of traditional monoclonal antibodies by enhancing potency and selectivity. Although the company generated significant early interest in the immuno-oncology space, it appears to have ceased active operations or transitioned into a stealth/dormant state following the departure of its founding executive team.